- Home
- NXP vs CRMD Comparison
NXP vs CRMD Comparison
Compare NXP & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXP | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 191 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.2M | 618.2M |
| IPO Year | 1995 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NXP | CRMD |
|---|---|---|
| Price | $14.02 | $7.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | 123.3K | ★ 959.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.84 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $13.73 | $6.13 |
| 52 Week High | $14.65 | $17.43 |
Technical Indicators
Market Signals| Indicator | NXP | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 57.36 |
| Support Level | $13.91 | $7.05 |
| Resistance Level | $14.04 | $8.53 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 2.07 | 56.99 |
Price Performance
Historical ComparisonAbout NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.